Cipla Limited

Cipia Limited

Pathi, Srinivas Laxminarayan

Rao, Dharmaraj Ramachandra

Kankan, Rajendra Narayanrao

Dharmaraj Ramachandra Rao

Rajendra Narayanrao Kankan

Srinivas Laxminarayan Pathi

Manjinder Singh Phull

Maruti Ganpati Ghagare

Dilip Ramdas Birari

Manish Gopaldas Gangrade

Ravikumar Puppala

Ashwini Amol Sawant

Geena Malhotra

Sunilkumar Parasnath Saroj

Yusuf Khwaja Hamied

Sandip Vasant Chikhalikar

Vinod Parameshwaran Acharya

Shrikant Suresh Mudgal

Shashirekha Kanathala

Revikumar Puppala

Venkata Sriram Pullela

Venkata Srinivas Pullela

Alka Chaudhary

Venugopalarao Chinimilli

Jayamadhava P Relekar

Pathi L Srinivas

Dilip Ramda Birari

Muruti Ghagare

Geena Malhortra

Vaishali Vaman Haldavanekar

Mangesh Prabhu

Manohar Raghunath Surve

Suryanarayana Durga Yarra

Swati Atul Kadam

Sachin Vasant Desai

Sanoj Thoppil

Nagarjuna Reddy Vantadou

Gopalakrishna Sumana Bangalore

Nayan Shivalkar

Shashi Rekha Kanathala

Nitin Thakur

Vidyadhar Purushottam Pande

Sumana Gopalakrishna Bangalore

Maruti Ghagare

Vaman Vaishali Haldavanekar

Dilip Birari

Puppala Ravikumar

Pathi Srinivas

Manjinder Singh

Pathi Laxminarayan Srinivas

Vinod Acharya

Cipla Ltd

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Rifaximin

There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.

Rifaximin complexes

The present invention relates to certain acid salts of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy) phosphoryloxy)methyl pivalate of Formula (I), to processes for their preparation; to pharmaceutical compositions comprising such compounds, and methods of treating a disease which responds to inhibition of nucleotide reverse transcriptase activity.

Salts of antiviral phosphonate analogues and process for preparation thereof

The present application relates to a process for the preparation of piperine of high purity having low concentrations of isomeric impurities.

Process for the preparation of piperine

The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

Polymorphic form X of nilotinib dihydrochloride hydrate

Amorphous methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1-(((2S)-2-(5-(4&#x2032;-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride, methods of making them, and pharmaceutical compositions containing them.

Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof

The present invention relates to novel processes for the preparation of apremilast of formula I, or a pharmaceutically acceptable salt thereof. 

Process for the preparation of apremilast

The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying out the novel process.

Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof

A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art.

Process for the preparation of bortezomib mannitol ester

The present invention relates to a novel process for the synthesis of everolimus of formula (I): and intermediates thereof.

Process for the synthesis of everolimus and intermediates thereof

Growing community of inventors

Maharashtra, India

Dharmaraj Ramachandra Rao